Xinnate currently develops the first application with BioC as the active product ingredient. The product, a treatment gel for burn wounds, is in pre-clinical phase and we expect to have clinical proof of concept during 2020. Next step is to further exploit the BioC platform and develop a diverse portfolio of skin and wound care applications.

The overall strategy is to develop each drug concept to a point when a commercial deal with a larger pharmaceutical company with global presence can be realized. Such transactions may include out-licensing-partnering/licensing, strategic partnerships, joint ventures or sales of the assets.

Read more about our: